Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BDB001 in advanced solid tumors after anti-PD-1/PD-L1 failure
NCT04819373Phase 2Completed
- Sponsor
- Eikon Therapeutics
- Start
- Aug 2021
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BDB001 in non-small cell lung cancer (NSCLC), cutaneous squamous cell carcinoma (cSCC), head and neck squamous cell carcinoma (HNSCC) and 4 more, sponsored by Eikon Therapeutics. Primary endpoint: Objective Response Rate at 2 years. Started Aug 2021; status: completed.
02
Drugs
BDB001
03
Conditions
non-small cell lung cancer (NSCLC)cutaneous squamous cell carcinoma (cSCC)head and neck squamous cell carcinoma (HNSCC)melanomaMerkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT04819373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04819373.